Skip to content

Study · Case report or series · n = 1 · 2020

5 results

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.

Iepsen EW, Have CT, Veedfald S, Madsbad S, Holst JJ, Grarup N, Pedersen O, Brandslund I, Holm JC, Hansen T, Torekov SS

Cell reports. Medicine21 Apr 2020Cited by 28 (Europe PMC)

PMID33205056 (opens in a new tab)PMCIDPMC7659505 (opens in a new tab)DOI10.1016/j.xcrm.2020.100006 (opens in a new tab)PepBankPUB-33205056
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with morbid obesity, type 2 diabetes and a homozygous pathogenic MC4R mutation, 16 weeks of liraglutide 3 mg/day gave a body weight loss of 9.7 kg.

    In plain wordsIn one woman with obesity and diabetes due to an MC4R gene mutation, liraglutide led to a 9.7 kg weight loss in 16 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight loss
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg/day · 16 weeksAs given in this study (human).

    Measurements

    Body weight loss
    9.7 kg
    16 weeks of liraglutide

    Source sentences

    Summary
    The body weight loss was 9.7 kg, similar to weight loss in heterozygous MC4R mutation carriers and common obesity.
    1 context sentence
    Summary · context
    Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with morbid obesity, type 2 diabetes and a homozygous pathogenic MC4R mutation, liraglutide led to a clinically relevant decrease in fasting glucose.

    In plain wordsIn one woman with obesity and diabetes due to an MC4R gene mutation, liraglutide lowered fasting blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting glucose
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 mg/day · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance.
    1 context sentence
    Summary · context
    Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation.
  3. 03HumanCase report or seriesEfficacy outcome

    In a woman with morbid obesity, type 2 diabetes and a homozygous pathogenic MC4R mutation, liraglutide led to a clinically relevant decrease in triglycerides.

    In plain wordsIn one woman with obesity and diabetes due to an MC4R gene mutation, liraglutide lowered blood triglycerides.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglycerides
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    3 mg/day · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance.
    1 context sentence
    Summary · context
    Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation.
  4. 04HumanCase report or seriesEfficacy outcome

    In a woman with morbid obesity, type 2 diabetes and a homozygous pathogenic MC4R mutation, liraglutide led to a clinically relevant decrease in systolic blood pressure.

    In plain wordsIn one woman with obesity and diabetes due to an MC4R gene mutation, liraglutide lowered systolic blood pressure.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    3 mg/day · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance.
    1 context sentence
    Summary · context
    Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation.
  5. 05HumanCase report or seriesEfficacy outcome

    In a woman with morbid obesity, type 2 diabetes and a homozygous pathogenic MC4R mutation, liraglutide treatment led to normalization of glucose tolerance.

    In plain wordsIn one woman with obesity and diabetes due to an MC4R gene mutation, glucose tolerance returned to normal with liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableGlucose tolerance
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 mg/day · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    In addition, the treatment led to clinically relevant decreases in fasting glucose, triglycerides, systolic blood pressure, and normalization of glucose tolerance.
    1 context sentence
    Summary · context
    Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07302802

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Prof. Dr. Martin Wabitschn = 701 Dec 2025 to est. Dec 2028

Monogenic Obesity

Trial pageClinicalTrials.govUpdated 8 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.